PeptideCompareZP6590 — EU research guide.
ZP6590 is Zealand Pharma's investigational long-acting GIP receptor agonist, designed not as a standalone obesity drug but as a co-formulation partner that boosts the effect of GLP-1 medicines like semaglutide.
What is ZP6590?
In preclinical models, ZP6590 has little weight-loss effect alone but substantially amplifies the weight loss produced by GLP-1 monotherapy when combined — the same ‘dual agonism’ logic behind tirzepatide, but as two separate co-dosed molecules instead of one hybrid peptide.
What does the research show?
As of Zealand Pharma's August 2026 half-year report, a first-in-human trial of ZP6590 in obesity has been started; the compound is positioned as a future combination partner alongside the company's more advanced amylin analogue, petrelintide.
EU legal status
Not approved anywhere; a very early-stage, single-sponsor investigational candidate with no legitimate research-peptide supply route.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ Modelled per compound from molecular structure — chain length, cyclisation, oxidation- and deamidation-prone residues and light sensitivity. Indicative only, not lab-measured per batch.
GLP-1/GIP compounds across EU suppliers
COA-verified EU vendors · Updated monthly
References
- The sponsor's description of ZP6590 as a long-acting GIP receptor agonist for co-formulation, with the preclinical findings and a note that it is unapproved everywhere. A company page, not independent evidence. Zealand Pharma. ZP6590: long-acting GIP receptor agonist for obesity. Pipeline page, accessed September 2026. Source
- The sponsor's half-year report (13 August 2026), stating that a first-in-human trial with ZP6590 has been started. It gives no data. Zealand Pharma. Zealand Pharma announces financial results for the first half of 2026. Company announcement; 13 August 2026. Source
- The mouse poster behind the main preclinical claim: negligible effect alone, added weight loss on top of semaglutide. Company data, presented at a conference, animal only. Nansen A, Rosenqvist H, Skarbaliene J. Anti-obesity effects of GIP analogue ZP6590 in combination with semaglutide in DIO mice. Poster; ObesityWeek 2022. Source
- Sponsor announcement of two posters at the 2022 Obesity Society meeting (mouse weight data and a ferret antiemetic model). It repeats the sponsor's own preclinical findings. Zealand Pharma. Zealand Pharma announces presentations at The Obesity Society annual meeting (posters on ZP6590 in DIO mice and in ferrets). Company announcement; 1 November 2022. Source
- Trade-news report on the first-in-human registry entry (randomised, triple-blinded, single and multiple ascending doses, recruiting). A secondary source; the registry record itself was not opened. Research vials sold online are not a licensed medicine and none exists. TipRanks. Zealand Pharma advances first-in-human obesity drug trial with ZP6590. News report on the registry entry (first submitted 16 July 2026). Source